I am double board-certified in Interventional Pain Medicine and Physical Medicine and Rehabilitation; and I have become deeply engrained in the psychedelic industry through my practice over the years. As a physician providing ketamine-assisted psychotherapy for both chronic pain and mental health conditions, I am excited to offer new solutions that will shape the future of medicine incorporating safe and effective psychedelic options. In addition, my research around ketamine has been as continuous as my involvement in the overall industry as a clinical advisor. Nucleus’ approach to the industry is unique and fills an enormous void. I am investing in Nucleus because I believe Nucleus’ assets will help propel the industry forward and ultimately help billions of people heal with and experience psychedelic medicines.